Skip to main content

F-star Therapeutics, Inc.

FSTXDelisted Mar 9, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001566373

F-star Therapeutics, Inc. was delisted on Mar 9, 2023; its insiders filed their last Form 4 on Mar 9, 2023; 59 institutions reported holding it in 13F filings for Q4 2022, worth $57.8M in total; Fairfax Financial was the only superinvestor holding it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:32 PM ET

Revenue flow, FY2021

Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2021: $31.3M (147.8% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of F-star Therapeutics, Inc., annual
Line itemFY2021FY2020FY2019FY2018FY2017
Period endDec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Filing10-K10-K10-K10-K10-K
ReportedMar 14, 2022Mar 29, 2021Jan 29, 2020––
Revenue$21.2M$11.3M–––
Research and development$28.8M$14.1M$23.3M$19.8M$13.1M
Selling, general and administrative$23.1M$19.5M$9.75M$8.72M$8.18M
Operating income-$30.7M-$22.4M-$33.0M-$28.5M-$21.3M
Interest expense$844.0K–$542.0K––
Income tax-$372.0K-$1.00K$0$0$0
Net income-$31.3M-$25.6M-$24.1M-$22.9M-$27.7M
EPS, basic––$-1.46$-1.59–
EPS, diluted––$-1.46$-1.88–
Weighted shares, basic––16.5M14.4M–
Weighted shares, diluted––16.5M14.6M–
Margins and growth
Operating margin-145.1%-198.9%–––
Net margin-147.8%-227.6%–––
Revenue growth, year over year+88.1%––––

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of F-star Therapeutics, Inc., annual
Line itemFY2021FY2020FY2019FY2018FY2017
Period endDec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Filing10-K10-K10-K10-K10-K
ReportedMar 14, 2022Mar 29, 2021Jan 29, 2020––
Cash and equivalents$78.5M$18.5M$28.7M$14.7M$23.6M
Short-term investments––$25.7M$32.9M$26.9M
Total current assets$84.7M$26.1M$58.0M$49.3M$51.1M
Property, plant and equipment$887.0K$789.0K$2.23M$2.32M$687.0K
Goodwill$14.9M$14.9M–––
Intangible assets$18.8M$19.0M–––
Total assets$123.0M$63.6M$63.2M$68.8M$52.3M
Accounts payable$3.08M$4.60M$2.21M$1.88M$1.70M
Short-term debt–$0–––
Total current liabilities$12.1M$17.0M$5.41M$4.25M$4.43M
Long-term debt$9.61M–$19.1M––
Total liabilities$26.2M$20.6M$27.7M$13.0M$17.6M
Shareholders' equity$96.9M$43.0M$35.5M$55.9M$34.7M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of F-star Therapeutics, Inc., annual
Line itemFY2021FY2020FY2019FY2018FY2017
Period endDec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Filing10-K10-K10-K10-K10-K
ReportedMar 14, 2022Mar 29, 2021Jan 29, 2020––
Operating cash flow-$27.3M-$16.2M-$29.1M-$25.2M–
Capital expenditures$658.0K–$272.0K$1.97M$323.0K
Free cash flow-$27.9M–-$29.3M-$27.2M–
Depreciation and amortization––$357.0K$288.0K$158.0K
Stock-based compensation$6.90M$3.49M$3.37M$2.78M$1.91M
Investing cash flow-$643.0K$14.0M$23.5M-$25.1M–
Financing cash flow$88.1M$15.8M$19.5M$41.2M–
Net change in cash$60.2M$13.7M$14.0M-$9.18M$13.4M
Ratio
Stock-based compensation, % of revenue32.6%31.0%–––

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for F-star Therapeutics, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Sep 30, 202222.0M+6.6%SEC
Jun 30, 202221.6M+4.7%SEC
Mar 31, 202221.5M+136.2%SEC
Mar 1, 202221.1M+131.5%SEC
Nov 8, 202120.6M+19.4%SEC
Aug 7, 202120.6M+19.5%SEC
May 12, 202119.4M+13.3%SEC
Mar 24, 20219.10M−46.8%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.